Communiqués SCYNEXIS, Inc.

Actions

SCYX

US8112923094

Produits pharmaceutiques

Temps réel estimé Cboe BZX 17:52:17 25/09/2026			Varia. 5j.	Varia. 1 janv.
4,470 ^USD	+0,45 %		+0,22 %	-11,65 %

22/09	SCYNEXIS, Inc. annonce la nomination de Steven K. Burke, M.D., à son conseil d’administration, à compter du 18 septembre 2026	CI
15/09	Scynexis, Inc. nomme Todd Minga au poste de Senior Vice President, Research & Development, à compter du 14 septembre 2026	CI

Communiqués

22/09	SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors	AQ
15/09	SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development	AQ
10/09	SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer	AQ
01/09	SCYNEXIS to Participate in Upcoming Investor Conferences	AQ
26/08	SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	AQ
10/08	Scynexis: Q2 Earnings Snapshot	AQ
10/08	SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
30/06	SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	AQ
22/05	SCYNEXIS Announces One-for-Eight Reverse Stock Split	AQ
11/05	Scynexis: Q1 Earnings Snapshot	AQ
11/05	SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
07/05	SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	AQ
31/03	SCYNEXIS Announces $40.0 Million Private Placement	AQ
31/03	SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	AQ
04/03	Scynexis: Q4 Earnings Snapshot	AQ
04/03	SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update	AQ
26/02	SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247	AQ
29/01	SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting	AQ
28/01	SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)	AQ
21/01	SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247	AQ
22/12	SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement	AQ
19/11	SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK	AQ
17/11	Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections	AQ
05/11	Scynexis: Q3 Earnings Snapshot	AQ
05/11	SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ